UBS Adjusts Price Target on Revolution Medicines to $220 From $175, Maintains Buy Rating
Revolution Medicines (RVMD) has an average rating of buy and mean price target of $196.86, according to analysts polled by FactSet. ( covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: ) Price: $191.11, Change: $+1.87, Percent Change: +0.99%
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.